This report provides details of the latest preclinical agreements announced in the healthcare sector.
Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases and databases do not.
This report contains a comprehensive listing of over 2,000 preclinical stage partnering deals announced since 2012 including financial terms, where available, including links to online deal records of actual preclinical partnering deals as disclosed by the deal parties. In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners.
Contract documents provide the answers to numerous questions about a prospective partner’s flexibility on a wide range of important issues, many of which will have a significant impact on each party’s ability to derive value from the deal.
The initial chapters of this report provide an orientation of preclinical stage deal making and business activities. Chapter 1 provides an introduction to the report, whilst Chapter 2 provides an overview of why companies partner preclinical stage compounds/products.
Chapter 3 provides an overview of preclinical stage deals strategy and deal structure including numerous case studies. Chapter 4 provides an overview of the various payment strategies used in preclinical stage deals.
Chapter 5 provides a review of preclinical stage deal making since 2012. Deals activity is reviewed by year, stage of development at signing, therapeutic area, technology type, as well as most active dealmakers.
Chapter 6 provides a detailed analysis of preclinical stage payment terms including headline, upfront, milestone and royalty rates.
Chapter 7 provides a review of the leading preclinical stage deal by headline value. Each deal title links via Current Agreements deals and alliances database to an online version of the full deal record, and where available, the actual contract document, providing easy access to each deal record on demand.
Chapter 8 provides a comprehensive listing of the top 50 most active preclinical stage dealmaker companies. Each deal title links via Current Agreements deals and alliances database to an online version of the full deal record, and where available, the actual contract document, providing easy access to each deal record on demand.
Chapter 9 provides a comprehensive and detailed review of preclinical stage partnering deals signed and announced since 2012, where a contract document is available in the public domain.
Chapter 1 provides a comprehensive directory of preclinical stage partnering deals since 2012.
The report includes deals announced by hundreds of life science companies including big pharma such as Abbott, Abbvie, Actavis, Amgen, Astellas, AstraZeneca, Baxter, Bayer, Biogen Idec, BMS, Celgene, Eisai, Eli Lilly, Gilead, GSK, J&J, Kyowa Hakko, Merck, Mitsubishi, Mylan, Novartis, Pfizer, Roche, Sanofi, Shire, Takeda, Teva, and Valeant, amongst many others.
The report also includes numerous tables and figures that illustrate the trends and activities in preclinical stage partnering and deal making since 2012.
In addition, a comprehensive appendix of all preclinical deals since 2012 is provided organized by partnering company A-Z, deal type, therapy focus and technology type. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of preclinical stage products and compounds.
Global Preclinical Stage Partnering Terms and Agreements in Pharma and Biotech 2012-2018 provides the reader with the following key benefits
In-depth understanding of preclinical stage deal trends since 2012
Access to headline, upfront, milestone and royalty data
Analysis of the structure of preclinical stage agreements with numerous real life case studies
Insight into the terms included in a preclinical stage agreement, together with real world clause examples
Understand the key deal terms companies have agreed in previous deals
Undertake due diligence to assess suitability of your proposed deal terms for partner companies
Global Preclinical Stage Partnering Terms and Agreements in Pharma and Biotech 2012-2018 is intended to provide the reader with an in-depth understanding and access to preclinical stage deal trends and structure of deals entered into by leading companies worldwide.
Global Preclinical Stage Partnering Terms and Agreements in Pharma and Biotech 2012-2018 includes:
Trends in preclinical stage dealmaking in the biopharma industry since 2012
Analysis of preclinical stage deal structure
Access to headline, upfront, milestone and royalty data
Case studies of real-life preclinical stage deals
Access to over 2,000 preclinical stage deals
The leading preclinical stage deals by value since 2012
Most active preclinical stage dealmakers since 2012
The leading preclinical stage partnering resources
In Global Preclinical Stage Partnering Terms and Agreements in Pharma and Biotech 2012-2018, the available contracts are listed by:
Stage of development at signing
Specific therapy target
Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
The Global Preclinical Stage Partnering Terms and Agreements in Pharma and Biotech 2012-2018 report provides comprehensive access to available deals and contract documents for over 2,000 preclinical stage deals. Analyzing actual contract agreements allows assessment of the following:
What are the precise rights granted or optioned?
What is actually granted by the agreement to the partner company?
What exclusivity is granted?
What is the payment structure for the deal?
How aresalesand payments audited?
What is the deal term?
How are the key terms of the agreement defined?
How are IPRs handled and owned?
Who is responsible for commercialization?
Who is responsible for development, supply, and manufacture?
How is confidentiality and publication managed?
How are disputes to be resolved?
Under what conditions can the deal be terminated?
What happens when there is a change of ownership?
What sublicensing and subcontracting provisions have been agreed?
Which boilerplate clauses does the company insist upon?
Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
Which jurisdiction does the company insist upon for agreement law?
Chapter 1 – Introduction
Chapter 2 – Why do companies partner preclinical stage compounds?
2.2. The role of preclinical stage partnering
2.2.1. In-licensing at preclinical stage
2.2.2. Out-licensing at preclinical stage
2.3. Difference between discovery, preclinical and clinical stage deals
2.4. Reasons for entering into preclinical stage partnering deals
2.4.1. Licensors reasons for entering preclinical stage deals
2.4.2. Licensees reasons for entering preclinical stage deals
2.5. The future of preclinical stage partnering deals
Chapter 3 – Preclinical stage deal strategies and structure
3.2. At what stage do companies partner?
3.2.1. Partnering early in pharmaceutical / biotech
220.127.116.11. Discovery and preclinical stage partnering case studies
18.104.22.168.a. Case study: LEO Pharma - 4SC
22.214.171.124.b. Case study: Heptares Therapeutics - Cubist
126.96.36.199.c. Case study: Incyte – Agenus Bio
188.8.131.52.d. Case study: Janssen Pharmaceutical - Evotec
3.2.2. Partnering later in pharmaceutical/biotech
184.108.40.206. Clinical stage partnering case studies
220.127.116.11.a. Case study: Servier – GeNeuro
18.104.22.168.b. Case study: Teva – Xenon Pharmaceuticals
22.214.171.124.c. Case study: AstraZeneca - Ardelyx
126.96.36.199.d. Case study: Baxter – Onconova Therapeutics
3.3. Early and later stage partnering – a risk/cost comparison
3.4. What do companies spend on preclinical stage partnering?
3.5. Pure versus multi-component partnering deals
3.6. Pure licensing agreement structure
3.6.1. Example pure preclinical stage licensing agreements
3.6.1.a. Case study : Merck and Co. – Tesaro
3.6.1.b. Case study : Marina Biotech – Mirna Therapeutics
3.7. Multicomponent preclinical stage partnering agreements
3.7.1. Example multicomponent preclinical stage clauses
3.7.1.a. Case study: Eleven Biotherapeutics – ThromboGenics
3.7.1.b. Case study: Pfizer – InSite Vision
Chapter 4 – Preclinical stage partnering payment strategies
4.2. Preclinical stage payment strategies
4.3. Payment options
4.3.1. Headline values
4.3.2. Upfront payments
188.8.131.52. Conditionality of upfront payments
4.3.4. Convertible loans
4.3.6. R&D funding
4.3.7. Licensing fees
4.3.8. Milestone payments
4.3.9. Royalty payments
184.108.40.206. Issues affecting royalty rates
220.127.116.11. Royalties on combination products
18.104.22.168.a. Case study: Scripps Research Institute-Cyanotech
22.214.171.124. Guaranteed minimum/maximum annual payments
126.96.36.199. Royalty stacking
188.8.131.52. Royalties and supply/purchase contracts
4.3.11. Option payments
Chapter 5 – Trends in preclinical stage deal making
5.2. Preclinical stage partnering over the years
5.2.1. Attributes of preclinical deals
5.3. Preclinical stage partnering by deal type
5.4. Preclinical stage partnering by disease type
5.5. Partnering by preclinical stage technology type
5.6. Preclinical stage partnering by most active company since 2012
Chapter 6 – Payment terms for preclinical stage partnering
6.2. Guidelines for preclinical stage payment terms
6.2.1. Upfront payments
6.2.2. Milestone payments
6.2.3. Royalty payments
6.3. Preclinical stage payment terms – deal data analysis
6.3.1. Public data
6.3.2. Survey data
6.4. Payment terms analysis
6.4.1. Preclinical stage headline values
6.4.2. Preclinical stage deal upfront payments
6.4.3. Preclinical stage deal milestone payments
6.4.4. Preclinical stage royalty rates
Chapter 7 – Leading preclinical stage deals
7.2. Top preclinical stage deals by value
Chapter 8 – Top 50 most active preclinical stage dealmakers
8.2. Top 50 most active preclinical stage dealmakers
Chapter 9 – Preclinical stage partnering contracts directory
9.2. Preclinical stage deals with contracts 2012 to 2018
Chapter 10 – Preclinical stage deal making by development stage
10.2. Deals by preclinical stage
Appendix 1 – Preclinical stage dealmaking by companies A-Z
Appendix 2 – Preclinical stage dealmaking by industry sector
Appendix 3 – Preclinical stage dealmaking by stage of development
Appendix 4 – Preclinical stage dealmaking by therapy area
Appendix 5 – Preclinical stage dealmaking by technology type
Table of figures
Figure 1: Definition of discovery, preclinical and clinical phases in dealmaking
Figure 2: Agreements signed by phase of development (2012- 2018), % of all deals
Figure 3: Components of the pure licensing deal structure
Figure 4: Payment options for preclinical stage partnering deals
Figure 5: Issues affecting royalty rates
Figure 6: Preclinical stage partnering frequency since 2012
Figure 7: Preclinical stage partnering by deal type since 2012
Figure 8: Preclinical stage partnering by disease type since 2012
Figure 9: Preclinical stage partnering by technology type since 2012
Figure 10: Top 50 most active preclinical stage dealmakers since 2012
Figure 11: Review of upfront payments for preclinical stage deals
Figure 12: Review of milestone payments for preclinical stage deals
Figure 13: Review of royalty payments for preclinical stage deals
Figure 14: Preclinical stage deals with a headline value
Figure 15: Preclinical stage deals with an upfront value
Figure 16: Preclinical stage deals with a milestone value
Figure 17: Preclinical stage deals with a royalty rate value
Figure 18: Top preclinical stage deals by value since 2012
Figure 19: Most active preclinical stage dealmakers since 2012